Program
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F
Also written as “AZD0120”, “GC012F Injection” and “AZD0120 - Regimen 1”.
Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic · Immunoglobulin Light-chain Amyloidosis · Multiple Sclerosis · Scleroderma, Systemic, led by AstraZeneca.
Drug pageAutologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F: every studyAll 29 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 1212 open or running | phase 3since Jan 30, 2026 | Apr 18, 2023 | Feb 1, 2027phase 2 · NCT06530849 |
- Named in AstraZeneca’s own pipeline as
AZD0120
, phase 3, as of Oct 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 18, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT05850234 · 232 planned · United States
- Jan 23, 2024Phase 2 study in Multiple MyelomaNCT06235229 · 110 planned · China
- Jul 25, 2024Phase 2 study in Lupus Erythematosus, SystemicNCT06530849 · 20 enrolled · China
- Mar 12, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT06897930 · 150 planned · United States, Australia, Canada and more
- Jul 7, 2025Phase 2 study in Immunoglobulin Light-chain AmyloidosisNCT07081646 · 91 planned · United States, Canada, United Kingdom
- Jul 10, 2025Phase 1 study in Multiple MyelomaNCT07073547 · 40 planned · United States
- Oct 16, 2025Phase 2 study in Scleroderma, SystemicNCT07295847 · 27 planned · United States, Australia, Germany and more
- Oct 21, 20252 phase 1 studiesNCT07250269, NCT07224373
- Jan 30, 2026Phase 3 study in Multiple MyelomaPhase 3 reachedNCT07391657 · 508 planned · United States, Australia, Brazil and more
- Jul 1, 20262 phase 3 studies in Multiple MyelomaNCT07764978, NCT07735637
- Oct 21, 2026Primary completion moved from 2028-10-11 to 2028-11-02Date moved laterphase 3 · +1 months · NCT07735637
Ahead
- Feb 1, 2027Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06530849
- Oct 1, 2027Primary completion: phase 2 study in Multiple MyelomaNCT05850234
- Feb 22, 2028Primary completion: phase 2 study in Scleroderma, SystemicNCT07295847
- May 26, 2028Primary completion: phase 1 study in Multiple MyelomaNCT07073547
TargetBeta
“A preparation of autologous T-lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and fused to as of yet not fully elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic activ…”NCIt, read by Claude
“A preparation of autologous T-lymphocytes engineered to express two separate chimeric antigen receptors (CARs) targeting the tumor-associated antigens (TAAs) BCMA and CD19 and ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| BCMA-CD19 Compound CAR T Cellsrule | icell-gene-therapeutics | phase 1 | 3 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07735637Multiple Myeloma · United States, Australia, Brazil and more | 3 | Recruiting | Nov 2, 2028 | 750 |
| NCT07764978Multiple Myeloma · United States, Australia, Brazil and more | 3 | Recruiting | Jan 11, 2029 | 750 |
| NCT07391657Multiple Myeloma · United States, Australia, Brazil and more | 3 | Recruiting | Jun 14, 2028 | 508 |
| NCT07250269Immunoglobulin Light-chain Amyloidosis · China | 1 | Recruiting | Nov 24, 2028 | 12 |
| NCT07224373Multiple Sclerosis · United States, Australia, Canada and more | 1 | Recruiting | Dec 12, 2028 | 24 |
| NCT07295847Scleroderma, Systemic · United States, Australia, Germany and more | 2 | Recruiting | Feb 22, 2028 | 27 |
| NCT07073547Multiple Myeloma · United States | 1 | Recruiting | May 26, 2028 | 40 |
| NCT07081646Immunoglobulin Light-chain Amyloidosis · United States, Canada, United Kingdom | 2 | Recruiting | Aug 15, 2029 | 91 |
| NCT06897930Lupus Erythematosus, Systemic · United States, Australia, Canada and more | 2 | Recruiting | May 1, 2029 | 150 |
| NCT06530849Lupus Erythematosus, Systemic · China | 2 | Active, not recruiting | Feb 1, 2027 | 20 |
| NCT06235229Multiple Myeloma · China | 2 | Recruiting | Mar 2, 2026 | 110 |
| NCT05850234Multiple Myeloma · United States | 2 | Recruiting | Oct 1, 2027 | 232 |
How it is read
Names in the registry
- “AZD0120”, 8 entries
- “GC012F Injection”, 2 entries
- “AZD0120 - Regimen 1”, 1 entry
- “AZD0120 - Regimen 2”, 1 entry
- “GC012F”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 6 studies
- Lupus Erythematosus, Systemic, 2 studies
- Immunoglobulin Light-chain Amyloidosis, 2 studies
- Multiple Sclerosis, 1 study
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.